IL292265B2 - Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) - Google Patents
Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione)Info
- Publication number
- IL292265B2 IL292265B2 IL292265A IL29226522A IL292265B2 IL 292265 B2 IL292265 B2 IL 292265B2 IL 292265 A IL292265 A IL 292265A IL 29226522 A IL29226522 A IL 29226522A IL 292265 B2 IL292265 B2 IL 292265B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- day
- days
- cycle
- cll
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923955P | 2019-10-21 | 2019-10-21 | |
| US202063011147P | 2020-04-16 | 2020-04-16 | |
| PCT/US2020/056409 WO2021080936A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL292265A IL292265A (en) | 2022-06-01 |
| IL292265B1 IL292265B1 (en) | 2025-05-01 |
| IL292265B2 true IL292265B2 (en) | 2025-09-01 |
Family
ID=73452273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292265A IL292265B2 (en) | 2019-10-21 | 2020-10-20 | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11628172B2 (enExample) |
| EP (1) | EP4048279B1 (enExample) |
| JP (1) | JP7581345B2 (enExample) |
| KR (1) | KR20220103953A (enExample) |
| CN (2) | CN114885603A (enExample) |
| AU (1) | AU2020369497C1 (enExample) |
| CA (1) | CA3154510A1 (enExample) |
| CL (1) | CL2022000991A1 (enExample) |
| ES (1) | ES3066029T3 (enExample) |
| IL (1) | IL292265B2 (enExample) |
| MX (1) | MX2022004727A (enExample) |
| WO (1) | WO2021080936A1 (enExample) |
| ZA (1) | ZA202204446B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020369497C1 (en) * | 2019-10-21 | 2026-05-07 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| IL292375A (en) | 2019-10-21 | 2022-06-01 | Celgene Corp | Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use |
| AU2020372333B2 (en) * | 2019-10-21 | 2026-08-06 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| SMT202600194T1 (it) | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| HRP20231487T1 (hr) | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| CN114885602A (zh) * | 2019-10-21 | 2022-08-09 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法 |
| WO2026099206A1 (en) | 2024-11-05 | 2026-05-15 | Celgene Corporation | Therapy for the treatment of non-hodgkin lymphoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8648096B2 (en) | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| EP2981262A1 (en) | 2013-04-02 | 2016-02-10 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| US20170128448A1 (en) | 2014-07-11 | 2017-05-11 | Celgene Corporation | Combination therapy for cancer |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| AU2020369497C1 (en) * | 2019-10-21 | 2026-05-07 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
| AU2020372333B2 (en) * | 2019-10-21 | 2026-08-06 | Celgene Corporation | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| HRP20231487T1 (hr) | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| CN114885602A (zh) | 2019-10-21 | 2022-08-09 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法 |
-
2020
- 2020-10-20 AU AU2020369497A patent/AU2020369497C1/en active Active
- 2020-10-20 KR KR1020227016738A patent/KR20220103953A/ko active Pending
- 2020-10-20 ES ES20807936T patent/ES3066029T3/es active Active
- 2020-10-20 EP EP20807936.8A patent/EP4048279B1/en active Active
- 2020-10-20 JP JP2022523519A patent/JP7581345B2/ja active Active
- 2020-10-20 IL IL292265A patent/IL292265B2/en unknown
- 2020-10-20 WO PCT/US2020/056409 patent/WO2021080936A1/en not_active Ceased
- 2020-10-20 US US17/075,125 patent/US11628172B2/en active Active
- 2020-10-20 MX MX2022004727A patent/MX2022004727A/es unknown
- 2020-10-20 CN CN202080088934.9A patent/CN114885603A/zh active Pending
- 2020-10-20 CN CN202310077726.4A patent/CN115919870B/zh active Active
- 2020-10-20 CA CA3154510A patent/CA3154510A1/en active Pending
-
2022
- 2022-04-20 ZA ZA2022/04446A patent/ZA202204446B/en unknown
- 2022-04-20 CL CL2022000991A patent/CL2022000991A1/es unknown
-
2023
- 2023-03-09 US US18/119,679 patent/US20230210859A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020369497C1 (en) | 2026-05-07 |
| US20230210859A1 (en) | 2023-07-06 |
| JP7581345B2 (ja) | 2024-11-12 |
| US11628172B2 (en) | 2023-04-18 |
| KR20220103953A (ko) | 2022-07-25 |
| CL2022000991A1 (es) | 2022-11-11 |
| EP4048279C0 (en) | 2026-01-07 |
| AU2020369497B2 (en) | 2026-02-05 |
| JP2022552881A (ja) | 2022-12-20 |
| IL292265B1 (en) | 2025-05-01 |
| EP4048279B1 (en) | 2026-01-07 |
| ES3066029T3 (en) | 2026-05-11 |
| WO2021080936A1 (en) | 2021-04-29 |
| CN115919870B (zh) | 2024-07-02 |
| EP4048279A1 (en) | 2022-08-31 |
| ZA202204446B (en) | 2023-10-25 |
| CN114885603A (zh) | 2022-08-09 |
| CN115919870A (zh) | 2023-04-07 |
| AU2020369497A1 (en) | 2022-05-19 |
| US20210113574A1 (en) | 2021-04-22 |
| MX2022004727A (es) | 2022-05-13 |
| CA3154510A1 (en) | 2021-04-29 |
| IL292265A (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292265B1 (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) | |
| EP4282486A3 (en) | Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof | |
| FI3952880T3 (fi) | 2-(2,6-dioksopiperidin-3-yyli)-4-((2-fluori-4-((3-morfolinoatsetidin-1-yyli)metyyli)bentsyyli)amino)isoindoliini-1,3-dioni käytettäväksi non-hodgkinin lymfooman hoidossa | |
| JP2022527398A5 (enExample) | ||
| MX2025001619A (es) | Inhibidor de pde4b y uso del mismo | |
| JP2022552881A5 (enExample) | ||
| TNSN05163A1 (fr) | Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases | |
| IL305910B1 (en) | Oral dosage formulation of {[ 5-(3- (chlorophenyl)- 3-hydroxypyridine-2- carbonyl] amino} acetic acid | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| TW201822769A (zh) | 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合 | |
| MX2024010863A (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2). | |
| EP4599894A3 (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| PE20200741A1 (es) | Composiciones farmaceuticas y metodos para tratar enfermedades cardiovasculares | |
| MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
| ZA202501471B (en) | Preparation and use of quinazolinone derivative as kinase inhibitor | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| WO2024173556A3 (en) | Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| US20210015809A1 (en) | Iloperidone metabolite for use in the treatment of psychiatric disorders | |
| MX2022004197A (es) | Inhibidores del factor d del complemento para administracion oral. | |
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| MX2024000999A (es) | Antagonista de molécula pequeña de lpa1. | |
| AU2020235187A8 (en) | Uses of phosphodiesterase inhibitors | |
| JP2021523138A5 (enExample) | ||
| MX2025011536A (es) | Forma polimorfica del clorhidrato de pitolisant |